StockpollyBeta
Get App
Popularity #3,603
KZIA · NASDAQ · Biotechnology

Kazia Therapeutics (ADR) (KZIA)

Develops paxalisib and licensed oncology programs for treatment-resistant cancers.

$10.10
vs last close−0.82 (−7.55%)

In millions of USD, except per-share figures · converted from AUD at the latest rate

In millionsQ4 FY20Jun 2020Q2 FY21Dec 2020Q4 FY21Jun 2021Q2 FY22Dec 2021Q4 FY22Jun 2022Q2 FY23Dec 2022Q4 FY23Jun 2023Q2 FY24Dec 2023Q4 FY24Jun 2024Q2 FY25Dec 2024Q4 FY25Jun 2025Q2 FY26Dec 2025
Revenue0011000002000
Gross profit0011000002000
5511918107616759
Research & development428867439323
132223336426
Selling & marketing000000000000
General & administrative132223336400
Other expenses000090000000
Operating income−5−50−9−18−10−7−6−14−7−3−9
00−20100201−1−51
Interest income000000000000
Other non-operating income0000−90000040
Income before tax−5−5−2−10−8−10−5−6−13−7−8−9
Income tax expense0000000000−10
Net income from continuing operations−5−4−1−9−8−10−5−6−13−7−7−9
Net income−5−4−1−9−8−10−5−6−13−7−7−9
EPS, basic−$27.29−$20.85−$5.49−$35.21−$31.27−$32.85−$10.63−$12.96−$21.97−$4.33−$4.51−$2.78
EPS, diluted−$27.29−$20.85−$5.49−$35.21−$31.27−$32.85−$10.63−$12.96−$21.97−$4.33−$4.51−$2.78
Weighted average shares, basic000000001123
Weighted average shares, diluted000000001123
EBITDA−4−41−9−8−9−7−6−13−6−3−9
Depreciation & amortization001111111100
EBIT−5−50−9−8−10−7−6−14−7−3−9